Novartis Hit With Challenge To Blood Pressure Drug IP
Generics drugs manufacturer Accord has taken aim at Novartis' protections over a blend of two blood pressure drugs, telling a London court that the combination of both medicines is not inventive....To view the full article, register now.
Already a subscriber? Click here to view full article